Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model

Journal of Urology

Volumn 168, Issue 2, 2002, Pages 756-761

  Ahmed, Sharmila ^a   Johnson, Candace S ^a   Rueger, Robert M ^a   Trump, Donald L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dexamethasone; Mitoxantrone; Prostate; Prostatic neoplasms; Vitamin D

Indexed keywords

ANDROGEN; CALCITRIOL; CRYSTAL VIOLET; DEXAMETHASONE; GLUCOCORTICOID; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PAIN; CELL CYCLE; CELL PROLIFERATION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TUMOR REGRESSION;

EID: 0036075032     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64740-4     Document Type: Article

References (31)

1. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
2. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
3. Fas ligand is constitutively secreted by prostate cancer cells in vitro
4. Antitumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs
5. Vitamin D in the prevention and treatment of prostate cancer
6. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo
7. Vitamin D: An antiproliferative agent with potential for therapy of squamous cell carcinoma
8. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis
9. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
10. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines
11. Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells
12. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent mek cleavage and up-regulation of mekk-1
13. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
14. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group
15. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma
16. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
17. High dose calcitriol (1,25(OH)2 calcitriol3) + dexamethasone in androgen independent prostate cancer (AIPC)
18. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone
19. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
20. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity
21. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice
22. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells
23. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells
24. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death
25. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage
26. Cis-diamminedichloroplatinum(II) cross-linking of the human myeloid cell nuclear differentiation antigen to DNA in HL-60 cells following 1,25-dihydroxy vitamin D3-induced monocyte differentiation
27. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
28. Phase II study of mitoxantrone, VP-16, and low-dose prednisone treatment response among men with hormone independent and resistant prostate cancer
29. A pilot study of mitoxantrone, estramustine, paclitaxel and hydrocortisone (METH) in patients with hormone refractory prostate cancer
30. A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate
31. Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel